UA75673C2 - Pharmaceutical composition containing proton pump inhibitor and antacids, processes for manufacture of tablets and method for treatment - Google Patents

Pharmaceutical composition containing proton pump inhibitor and antacids, processes for manufacture of tablets and method for treatment Download PDF

Info

Publication number: UA75673C2
Authority: UA; Ukraine
Prior art keywords: tablet according; items; omeprazole; tablet; differs
Prior art date: 2001-07-16

Application number

UA2004010288A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-16

Filing date

2002-10-07

Publication date

2006-05-15

2002-10-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-05-15 Publication of UA75673C2 publication Critical patent/UA75673C2/uk

Links

239000003159 antacid agent Substances 0.000 title claims abstract description 63
229940069428 antacid Drugs 0.000 title claims abstract description 58
238000000034 method Methods 0.000 title claims abstract description 21
238000011282 treatment Methods 0.000 title claims abstract description 11
238000004519 manufacturing process Methods 0.000 title claims abstract description 7
229940126409 proton pump inhibitor Drugs 0.000 title claims description 34
239000000612 proton pump inhibitor Substances 0.000 title claims description 34
239000008194 pharmaceutical composition Substances 0.000 title 1
239000011248 coating agent Substances 0.000 claims abstract description 100
238000000576 coating method Methods 0.000 claims abstract description 100
230000004888 barrier function Effects 0.000 claims abstract description 59
239000008187 granular material Substances 0.000 claims abstract description 56
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 53
239000000203 mixture Substances 0.000 claims abstract description 50
230000001458 anti-acid effect Effects 0.000 claims abstract description 42
229920001577 copolymer Polymers 0.000 claims abstract description 25
239000003795 chemical substances by application Substances 0.000 claims abstract description 17
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 13
239000000314 lubricant Substances 0.000 claims abstract description 8
239000003085 diluting agent Substances 0.000 claims abstract description 7
239000003765 sweetening agent Substances 0.000 claims abstract description 6
229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 5
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims abstract description 4
230000008961 swelling Effects 0.000 claims abstract description 4
235000010216 calcium carbonate Nutrition 0.000 claims abstract description 3
239000003086 colorant Substances 0.000 claims abstract description 3
230000002401 inhibitory effect Effects 0.000 claims abstract description 3
102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 claims abstract 2
108010083204 Proton Pumps Proteins 0.000 claims abstract 2
230000001681 protective effect Effects 0.000 claims abstract 2
239000003826 tablet Substances 0.000 claims description 91
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 58
229960000381 omeprazole Drugs 0.000 claims description 54
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 50
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 38
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
235000019359 magnesium stearate Nutrition 0.000 claims description 25
239000008213 purified water Substances 0.000 claims description 20
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 19
239000000377 silicon dioxide Substances 0.000 claims description 19
235000012239 silicon dioxide Nutrition 0.000 claims description 19
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 16
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 16
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 16
229960000913 crospovidone Drugs 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 16
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 16
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 16
239000000600 sorbitol Substances 0.000 claims description 16
235000010356 sorbitol Nutrition 0.000 claims description 16
108010011485 Aspartame Proteins 0.000 claims description 13
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
239000000605 aspartame Substances 0.000 claims description 13
235000010357 aspartame Nutrition 0.000 claims description 13
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
229960003438 aspartame Drugs 0.000 claims description 13
239000010410 layer Substances 0.000 claims description 13
229930195725 Mannitol Natural products 0.000 claims description 12
KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 claims description 12
239000000594 mannitol Substances 0.000 claims description 12
235000010355 mannitol Nutrition 0.000 claims description 12
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 11
238000004090 dissolution Methods 0.000 claims description 11
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
239000008108 microcrystalline cellulose Substances 0.000 claims description 10
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
-1 alkali metal salt Chemical class 0.000 claims description 9
239000004408 titanium dioxide Substances 0.000 claims description 9
239000002826 coolant Substances 0.000 claims description 8
238000000354 decomposition reaction Methods 0.000 claims description 8
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
229960003943 hypromellose Drugs 0.000 claims description 8
229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
239000007916 tablet composition Substances 0.000 claims description 7
239000000454 talc Substances 0.000 claims description 7
229910052623 talc Inorganic materials 0.000 claims description 7
239000007884 disintegrant Substances 0.000 claims description 6
MQEUGMWHWPYFDD-UHFFFAOYSA-N magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Mg].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-UHFFFAOYSA-N 0.000 claims description 6
229960003117 omeprazole magnesium Drugs 0.000 claims description 6
230000035699 permeability Effects 0.000 claims description 6
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 5
239000007910 chewable tablet Substances 0.000 claims description 5
229940068682 chewable tablet Drugs 0.000 claims description 5
229960005168 croscarmellose Drugs 0.000 claims description 5
239000000796 flavoring agent Substances 0.000 claims description 5
159000000011 group IA salts Chemical class 0.000 claims description 5
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
235000021092 sugar substitutes Nutrition 0.000 claims description 5
239000000811 xylitol Substances 0.000 claims description 5
235000010447 xylitol Nutrition 0.000 claims description 5
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
229960002675 xylitol Drugs 0.000 claims description 5
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 4
229920002678 cellulose Chemical class 0.000 claims description 4
239000001913 cellulose Chemical class 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
239000011247 coating layer Substances 0.000 claims description 4
239000006185 dispersion Substances 0.000 claims description 4
239000011777 magnesium Substances 0.000 claims description 4
229910052749 magnesium Inorganic materials 0.000 claims description 4
229920005862 polyol Polymers 0.000 claims description 4
150000003077 polyols Chemical group 0.000 claims description 4
210000003296 saliva Anatomy 0.000 claims description 4
210000000813 small intestine Anatomy 0.000 claims description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
125000004432 carbon atom Chemical class C* 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 claims description 3
230000001055 chewing effect Effects 0.000 claims description 3
235000013355 food flavoring agent Nutrition 0.000 claims description 3
159000000003 magnesium salts Chemical group 0.000 claims description 3
125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
238000007908 dry granulation Methods 0.000 claims description 2
235000019634 flavors Nutrition 0.000 claims description 2
229960003174 lansoprazole Drugs 0.000 claims description 2
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
239000000845 maltitol Substances 0.000 claims description 2
235000010449 maltitol Nutrition 0.000 claims description 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
229940035436 maltitol Drugs 0.000 claims description 2
229960005019 pantoprazole Drugs 0.000 claims description 2
229960004157 rabeprazole Drugs 0.000 claims description 2
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 2
238000005507 spraying Methods 0.000 claims description 2
238000005550 wet granulation Methods 0.000 claims description 2
239000002702 enteric coating Substances 0.000 claims 6
238000009505 enteric coating Methods 0.000 claims 6
230000002708 enhancing effect Effects 0.000 claims 2
229910052783 alkali metal Inorganic materials 0.000 claims 1
125000005395 methacrylic acid group Chemical group 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract description 3
239000007931 coated granule Substances 0.000 abstract description 3
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract description 3
239000000347 magnesium hydroxide Substances 0.000 abstract description 3
229910001862 magnesium hydroxide Inorganic materials 0.000 abstract description 3
229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
235000003599 food sweetener Nutrition 0.000 abstract 1
229910001679 gibbsite Inorganic materials 0.000 abstract 1
235000012254 magnesium hydroxide Nutrition 0.000 abstract 1
239000008191 permeabilizing agent Substances 0.000 abstract 1
239000002253 acid Substances 0.000 description 26
210000000214 mouth Anatomy 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
238000005469 granulation Methods 0.000 description 12
230000003179 granulation Effects 0.000 description 12
238000004458 analytical method Methods 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000000872 buffer Substances 0.000 description 7
201000006549 dyspepsia Diseases 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
229910052782 aluminium Inorganic materials 0.000 description 6
208000035475 disorder Diseases 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
238000003825 pressing Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 4
239000000619 acesulfame-K Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
208000024798 heartburn Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
239000006191 orally-disintegrating tablet Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
150000003839 salts Chemical group 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
229940001496 tribasic sodium phosphate Drugs 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
208000004300 Atrophic Gastritis Diseases 0.000 description 2
208000036495 Gastritis atrophic Diseases 0.000 description 2
206010030216 Oesophagitis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
235000010358 acesulfame potassium Nutrition 0.000 description 2
229960004998 acesulfame potassium Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
208000016644 chronic atrophic gastritis Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 2
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
238000004049 embossing Methods 0.000 description 2
208000006881 esophagitis Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000013022 formulation composition Substances 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229940004916 magnesium glycinate Drugs 0.000 description 2
239000000391 magnesium silicate Substances 0.000 description 2
210000001711 oxyntic cell Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000013112 stability test Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001329 FEMA 3811 Substances 0.000 description 1
206010016322 Feeling abnormal Diseases 0.000 description 1
208000034991 Hiatal Hernia Diseases 0.000 description 1
206010020028 Hiatus hernia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229910000323 aluminium silicate Inorganic materials 0.000 description 1
229940118662 aluminum carbonate Drugs 0.000 description 1
UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 description 1
SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000004148 curcumin Substances 0.000 description 1
MPRVXUYAJZZBHG-UHFFFAOYSA-K dicarbonoperoxoyloxyalumanyl hydroxy carbonate Chemical compound [Al+3].OOC([O-])=O.OOC([O-])=O.OOC([O-])=O MPRVXUYAJZZBHG-UHFFFAOYSA-K 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
229940015828 dihydroxyaluminum sodium carbonate Drugs 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000030135 gastric motility Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229960001708 magnesium carbonate Drugs 0.000 description 1
229960000816 magnesium hydroxide Drugs 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229960000869 magnesium oxide Drugs 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000011325 microbead Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
235000010434 neohesperidine DC Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000008183 oral pharmaceutical preparation Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000004088 simulation Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229960001407 sodium bicarbonate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
230000001720 vestibular Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

UA2004010288A 2001-07-16 2002-10-07 Pharmaceutical composition containing proton pump inhibitor and antacids, processes for manufacture of tablets and method for treatment UA75673C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01401896		2001-07-16
PCT/SE2002/001370 WO2003007917A1 (en)	2001-07-16	2002-07-10	Pharmaceutical formulation comprising a proton pump inhibitor and antacids

Publications (1)

Publication Number	Publication Date
UA75673C2 true UA75673C2 (en)	2006-05-15

Family

ID=8182807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2004010288A UA75673C2 (en)	2001-07-16	2002-10-07	Pharmaceutical composition containing proton pump inhibitor and antacids, processes for manufacture of tablets and method for treatment

Country Status (24)

Country	Link
US (2)	US20040219211A1 (ru)
EP (1)	EP1416922A1 (ru)
JP (1)	JP2004536855A (ru)
KR (1)	KR20040018463A (ru)
CN (1)	CN100469366C (ru)
AR (1)	AR034757A1 (ru)
AU (1)	AU2002316020B2 (ru)
BG (1)	BG108515A (ru)
BR (1)	BR0211117A (ru)
CA (1)	CA2453290A1 (ru)
CO (1)	CO5550417A2 (ru)
HU (1)	HUP0401941A3 (ru)
IL (1)	IL159584A0 (ru)
IS (1)	IS7111A (ru)
MX (1)	MXPA04000385A (ru)
MY (1)	MY136137A (ru)
NO (1)	NO20040178L (ru)
NZ (1)	NZ530511A (ru)
PL (1)	PL367686A1 (ru)
RU (1)	RU2301662C2 (ru)
UA (1)	UA75673C2 (ru)
UY (1)	UY27385A1 (ru)
WO (1)	WO2003007917A1 (ru)
ZA (1)	ZA200400285B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1429738B1 (en)	2001-09-28	2007-10-31	McNEIL-PPC, INC.	Modified release dosage forms
DE10304403A1 (de)	2003-01-28	2004-08-05	Röhm GmbH & Co. KG	Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AR045068A1 (es) *	2003-07-23	2005-10-12	Univ Missouri	Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en)	2003-10-01	2012-09-11	Wyeth Corp	Pantoprazole multiparticulate formulations
CN100438914C (zh) *	2003-10-15	2008-12-03	富士化学工业株式会社	用于口腔内快速崩解的片剂的组合物
US8349361B2 (en)	2003-10-15	2013-01-08	Fuji Chemical Industry Co., Ltd.	Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) *	2003-10-15	2006-11-08	富士化学工業株式会社	口腔内速崩壊性錠剤用の組成物
WO2005044223A1 (en) *	2003-11-07	2005-05-19	Takeda Pharmaceutical Company Limited	Chewable tablet
US20050281876A1 (en)	2004-06-18	2005-12-22	Shun-Por Li	Solid dosage form for acid-labile active ingredient
EP1621187A1 (en) *	2004-07-26	2006-02-01	AstraZeneca AB	Pharmaceutical multiparticulate tablet formulations and process for their preparation
US8758814B2 (en)	2004-10-08	2014-06-24	Mcneil-Ppc, Inc.	Chewable enteric coated aspirin tablets
US8057820B2 (en)	2004-10-08	2011-11-15	Mcneil-Ppc, Inc.	Enteric coated aspirin granules comingled with binder
US8673352B2 (en)	2005-04-15	2014-03-18	Mcneil-Ppc, Inc.	Modified release dosage form
DE102005024614A1 (de) *	2005-05-25	2006-11-30	Röhm Gmbh	Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
US20080166407A1 (en) *	2005-07-29	2008-07-10	Shalaby Shalaby W	Solid oral formulations for combination therapy
CN100431526C (zh) *	2005-11-07	2008-11-12	上海艾力斯医药科技有限公司	一种酸敏感型药物的快速崩解片剂
CN101120930B (zh) *	2006-08-11	2010-09-29	石药集团中奇制药技术（石家庄）有限公司	一种奥美拉唑组合物及其制备方法
BRPI0822140A8 (pt)	2008-01-10	2022-07-05	Evonik Roehm Gmbh	Preparação farmacêutica ou nutracêutica revestida tendo liberação pulsada de subsatância ativa
CA2711475A1 (en) *	2008-01-10	2009-07-16	Evonik Roehm Gmbh	Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
WO2009112156A1 (en) *	2008-03-10	2009-09-17	Bayer Consumer Care Ag	Palatable solid composition comprising antacid and saliva stimulant
BRPI0909439A2 (pt)	2008-03-11	2015-12-15	Takeda Pharmaceutical	preparação sólida de desintegração oral, e, método para suprimir a ruptura de grânulos finos
WO2010054845A1 (en) *	2008-11-17	2010-05-20	Nycomed Pharma As	Improved dissolution stability of calcium carbonate tablets
CA2819460C (en) *	2010-12-03	2017-08-01	Takeda Pharmaceutical Company Limited	Orally disintegrating tablet
CN102085188B (zh) *	2011-01-14	2013-01-02	寿光富康制药有限公司	一种兰索拉唑肠溶微丸的制备方法
CN102078616A (zh) *	2011-01-28	2011-06-01	北京虹湾医药技术有限公司	埃索美拉唑碳酸氢钠组合物
US8277842B1 (en) *	2012-01-20	2012-10-02	Dart Neuroscience (Cayman) Ltd.	Enteric-coated HT-2157 compositions and methods of their use
CN102631327B (zh) *	2012-05-14	2013-08-28	海南葫芦娃制药有限公司	一种奥美拉唑肠溶微丸及其制备方法
CN103479593B (zh) *	2013-05-10	2014-10-08	青岛双鲸药业有限公司	一种奥美拉唑肠溶片的制备方法
JP6156037B2 (ja) *	2013-10-03	2017-07-05	ライオン株式会社	固形医薬製剤組成物
CN103784414B (zh) *	2013-12-18	2018-01-30	北京华禧联合科技发展有限公司	一种埃索美拉唑肠溶片及其制备方法
CA2910865C (en)	2014-07-15	2016-11-29	Isa Odidi	Compositions and methods for reducing overdose
WO2016174664A1 (en)	2015-04-29	2016-11-03	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US20190054069A1 (en) *	2016-02-03	2019-02-21	Novartis Ag	New use of a combination of sacubitril and valsartan
US20190151297A1 (en) *	2016-04-29	2019-05-23	Nauts Equine Brand Pty Ltd	Veterinary Composition
US10076494B2 (en) *	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
CN108434117A (zh) *	2018-03-29	2018-08-24	成都通德药业有限公司	一种奥美拉唑肠溶胶囊的制备方法
RU2727506C1 (ru) *	2019-09-09	2020-07-22	Пивипи Лабс Пте. Лтд.	Средство для лечения эректильной дисфункции
KR102531045B1 (ko) *	2020-01-23	2023-05-11	한미약품 주식회사	프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제
KR20220065997A (ko) *	2020-11-13	2022-05-23	(주)휴온스	라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CA3203975A1 (en)	2020-12-03	2022-06-09	Battelle Memorial Institute	Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CN114617852B (zh) *	2020-12-10	2023-06-27	昆药集团股份有限公司	一种奥美拉唑肠溶制剂及其制备方法
CN117500923A (zh)	2021-04-07	2024-02-02	巴特尔纪念研究院	用于鉴定和使用非病毒载体的快速设计、构建、测试和学习技术

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2516408B2 (ja) *	1988-08-18	1996-07-24	エスエス製薬株式会社	被覆顆粒を含む錠剤
DE4122217C2 (de) *	1991-07-04	1997-02-13	Merz & Co Gmbh & Co	Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5464632C1 (en) *	1991-07-22	2001-02-20	Prographarm Lab	Rapidly disintegratable multiparticular tablet
PT723436E (pt) *	1994-07-08	2002-02-28	Astrazeneca Ab	Forma de dosagem em comprimidos com unidades multiplas
SE9600071D0 (sv) *	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients I
DE19617487A1 (de) *	1996-05-02	1997-11-06	Merck Patent Gmbh	Geschmacksverbesserung von Arzneimittelwirkstoffen
JP3961596B2 (ja) *	1996-10-15	2007-08-22	富士化学工業株式会社	無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤
US6024981A (en) *	1997-04-16	2000-02-15	Cima Labs Inc.	Rapidly dissolving robust dosage form
KR100446366B1 (ko) *	1997-07-01	2004-09-01	화이자 인코포레이티드	서트랄린 염 및 서트랄린의 서방성 투여형
FR2766089B1 (fr) *	1997-07-21	2000-06-02	Prographarm Lab	Comprime multiparticulaire perfectionne a delitement rapide
CA2587022A1 (en) *	1998-05-18	1999-11-25	Takeda Pharmaceutical Company Limited	Orally disintegrable tablets
CA2374760A1 (en) *	1999-06-18	2000-12-28	Takeda Chemical Industries, Ltd.	Quickly disintegrating solid preparations
DE19954653B4 (de) *	1999-11-13	2006-01-19	Contitech Profile Gmbh	Extruder zur Aufbereitung von Kautschukmischungen
US6656492B2 (en) *	2000-06-30	2003-12-02	Yamanouchi Pharmaceutical Co., Ltd.	Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6749867B2 (en) *	2000-11-29	2004-06-15	Joseph R. Robinson	Delivery system for omeprazole and its salts
CN100335040C (zh) *	2000-12-07	2007-09-05	奥坦纳医药公司	含有酸敏感型活性成分的快速崩解片剂

2002
- 2002-07-10 CA CA002453290A patent/CA2453290A1/en not_active Abandoned
- 2002-07-10 US US10/484,064 patent/US20040219211A1/en not_active Abandoned
- 2002-07-10 JP JP2003513526A patent/JP2004536855A/ja active Pending
- 2002-07-10 RU RU2004101061/15A patent/RU2301662C2/ru not_active IP Right Cessation
- 2002-07-10 WO PCT/SE2002/001370 patent/WO2003007917A1/en active IP Right Grant
- 2002-07-10 CN CNB028180135A patent/CN100469366C/zh not_active Expired - Fee Related
- 2002-07-10 NZ NZ530511A patent/NZ530511A/en unknown
- 2002-07-10 EP EP02746288A patent/EP1416922A1/en not_active Withdrawn
- 2002-07-10 AU AU2002316020A patent/AU2002316020B2/en not_active Ceased
- 2002-07-10 MX MXPA04000385A patent/MXPA04000385A/es active IP Right Grant
- 2002-07-10 IL IL15958402A patent/IL159584A0/xx unknown
- 2002-07-10 BR BR0211117-9A patent/BR0211117A/pt not_active IP Right Cessation
- 2002-07-10 PL PL02367686A patent/PL367686A1/xx not_active Application Discontinuation
- 2002-07-10 KR KR10-2004-7000606A patent/KR20040018463A/ko not_active Application Discontinuation
- 2002-07-10 HU HU0401941A patent/HUP0401941A3/hu unknown
- 2002-07-10 AR ARP020102572A patent/AR034757A1/es unknown
- 2002-07-15 MY MYPI20022672A patent/MY136137A/en unknown
- 2002-07-16 UY UY27385A patent/UY27385A1/es unknown
- 2002-10-07 UA UA2004010288A patent/UA75673C2/uk unknown
2004
- 2004-01-06 BG BG108515A patent/BG108515A/xx unknown
- 2004-01-14 ZA ZA2004/00285A patent/ZA200400285B/en unknown
- 2004-01-15 NO NO20040178A patent/NO20040178L/no not_active Application Discontinuation
- 2004-01-15 IS IS7111A patent/IS7111A/is unknown
- 2004-01-16 CO CO04002774A patent/CO5550417A2/es not_active Application Discontinuation
2010
- 2010-06-10 US US12/813,018 patent/US20110135722A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040219211A1 (en)	2004-11-04
KR20040018463A (ko)	2004-03-03
UY27385A1 (es)	2003-02-28
WO2003007917A1 (en)	2003-01-30
ZA200400285B (en)	2005-06-29
JP2004536855A (ja)	2004-12-09
BG108515A (en)	2005-02-28
CA2453290A1 (en)	2003-01-30
IS7111A (is)	2004-01-15
MXPA04000385A (es)	2004-05-04
NZ530511A (en)	2005-06-24
AR034757A1 (es)	2004-03-17
MY136137A (en)	2008-08-29
RU2301662C2 (ru)	2007-06-27
CN100469366C (zh)	2009-03-18
NO20040178L (no)	2004-03-16
HUP0401941A3 (en)	2008-04-28
IL159584A0 (en)	2004-06-01
RU2004101061A (ru)	2005-04-20
AU2002316020B2 (en)	2007-03-15
CO5550417A2 (es)	2005-08-31
BR0211117A (pt)	2004-06-22
PL367686A1 (en)	2005-03-07
EP1416922A1 (en)	2004-05-12
CN1555256A (zh)	2004-12-15
HUP0401941A2 (hu)	2005-01-28
US20110135722A1 (en)	2011-06-09

Publication	Publication Date	Title
UA75673C2 (en)	2006-05-15	Pharmaceutical composition containing proton pump inhibitor and antacids, processes for manufacture of tablets and method for treatment
AU2002316020A1 (en)	2003-05-22	Pharmaceutical formulation comprising a proton pump inhibitor and antacids
US20220133778A1 (en)	2022-05-05	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AP1052A (en)	2002-03-21	Paroxetine controlled release compositions.
EP1194153B1 (en)	2004-05-06	Taste masked pharmaceutical liquid formulations
JPH11501951A (ja)	1999-02-16	プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形
US20150202226A1 (en)	2015-07-23	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2002530322A (ja)	2002-09-17	味隠蔽迅速放出コーティング系
US8906940B2 (en)	2014-12-09	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP4276545B2 (ja)	2009-06-10	改良組成物
HRP20040322A2 (en)	2004-12-31	Flashmelt oral dosage formulation
WO2007086846A1 (en)	2007-08-02	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP4549609B2 (ja)	2010-09-22	被覆固形催眠製剤
Singh et al.	2011	Effect of superdisintegrants in the formulation of taste-masked orodispersible tablets of Tizanidine HCl
CA2566655C (en)	2013-04-16	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100431526C (zh)	2008-11-12	一种酸敏感型药物的快速崩解片剂
AU2005331781B2 (en)	2011-09-29	Pharmaceutical formulations useful for inhibiting acid secretion
AU2011265561A1 (en)	2012-02-02	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them